The rollout of a preventative antibody treatment for Respiratory Syncytial Virus (RSV) is significantly reducing hospitalizations among infants in the Netherlands, offering a promising development in the fight against this common, yet potentially serious, childhood illness. Data released this month indicates a dramatic 75% decrease in RSV-related intensive care admissions compared to the same period last year. This success is largely attributed to the inclusion of the RSV antibody, known as nirsevimab, into the national vaccination program beginning in September 2025.
RSV is a highly contagious virus that causes infections of the lungs and respiratory tract. While often mild, particularly in older children and adults, it can be severe – and even life-threatening – for infants and young children. Symptoms can include bronchiolitis (inflammation of the slight airways in the lungs) and pneumonia. The virus typically circulates during the fall and winter months, placing a significant strain on healthcare systems. The introduction of nirsevimab represents a proactive step towards mitigating this seasonal burden and protecting the most vulnerable members of the population.
Dramatic Drop in ICU Admissions
Between September 29, 2025 and February 1, 2026, a total of 43 infants were admitted to Dutch pediatric intensive care units (ICUs) with RSV infections. According to the National Immunisation Programme, this is a stark contrast to the 178 infants hospitalized with RSV during the same period the previous year. This substantial reduction highlights the effectiveness of the preventative measure. The antibody is administered by youth healthcare services, and is currently being offered to babies born through the end of March, with earlier administration recommended for optimal protection.
How the RSV Antibody Works
Unlike traditional vaccines, nirsevimab is not a vaccine but a passive immunization. It provides infants with pre-formed antibodies against RSV, offering immediate protection. As explained by the GGD Drenthe, the antibody works by providing the baby with the tools to fight off the virus before they are even exposed, eliminating the need for the infant’s immune system to develop antibodies on its own. This protection lasts for approximately six months, covering the majority of the RSV season. Studies conducted in other European countries, including Spain, Portugal, and Belgium, have demonstrated an approximately 80% reduction in RSV-related hospitalizations following the implementation of similar antibody programs.
Targeted Immunization Schedule
The timing of the antibody administration is crucial for maximizing its protective effect. Babies born between October 1st and March 31st receive the antibody within two weeks of birth, typically during a home visit. Infants born between April 1st and September 30th receive the antibody in September or October at a consultation bureau. This phased approach ensures that all infants receive protection before the peak of the RSV season. Parents receive a letter from the GGD outlining the details of when and where their baby can receive the antibody.
Minimal Side Effects Reported
The RSV antibody has demonstrated a favorable safety profile. Reported side effects are generally mild and transient, including skin rash, redness or swelling at the injection site, and fever. The Landelijke Registratie Evaluatie Bijwerkingen (Lareb), the Netherlands’ national reporting center for adverse drug reactions, has received reports consistent with these findings. While fever in infants under three months of age could be a side effect of the antibody, healthcare professionals recommend contacting a physician to rule out other potential causes.
Positive Response from Healthcare Professionals
Pediatricians are expressing optimism regarding the impact of the RSV antibody program. Valerie Sloof, a pediatrician at the Wilhelmina Children’s Hospital, stated, “We are currently seeing a clear decrease in the number of patients with RSV infections in the pediatric ICU. The enormous pressure we normally experience on the availability of pediatric ICU beds during the winter has also decreased.” This reduction in hospitalizations not only benefits individual patients but also alleviates the strain on the healthcare system as a whole.
Understanding RSV and its Impact
RSV is a leading cause of lower respiratory tract infections in young children worldwide. The virus spreads through close contact with infected individuals, often via respiratory droplets produced during coughing or sneezing. Symptoms typically appear 4 to 6 days after infection and can include a runny nose, cough, fever, and difficulty breathing. While most children recover with supportive care, severe cases can require hospitalization and may lead to complications such as pneumonia and bronchiolitis. Infants, particularly those born prematurely or with underlying health conditions, are at the highest risk of severe illness.
The introduction of nirsevimab represents a significant advancement in the prevention of RSV-related morbidity and mortality. By providing passive immunity to infants, this antibody offers a crucial layer of protection during their first vulnerable months of life. The observed reduction in ICU admissions in the Netherlands underscores the potential of this preventative strategy to safeguard infant health and ease the burden on healthcare resources.
Looking ahead, ongoing monitoring and research will be essential to further evaluate the long-term effectiveness and impact of the RSV antibody program. Healthcare officials will continue to track hospitalization rates, assess the duration of protection, and monitor for any potential adverse effects. This data will inform future recommendations and ensure that the program remains optimized to protect the health of infants across the Netherlands.
The success of this program in the Netherlands may also serve as a model for other countries considering similar preventative measures against RSV. As more data becomes available, We see likely that the use of RSV antibodies will become increasingly widespread, offering hope for a future with fewer severe RSV infections in young children.
Stay informed about the latest developments in RSV prevention and treatment by consulting with your healthcare provider and visiting the website of the National Immunisation Programme. Your comments and questions are welcome below.